Peficitinib

• Description :

  Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].

• Product Name Alternative :

  ASP015K; JNJ-54781532

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  JAK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Peficitinib.html

• Purity :

  99.43

• Solubility :

  DMSO : 58.33 mg/mL (ultrasonic)

• Smiles :

  O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O

• Molecular Formula :

  C18H22N4O2

• Molecular Weight :

  326.39

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ito M, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017 Jan;133 (1) :25-33.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  JAK1; JAK2; JAK3; Tyk2

• CAS Number :

  [944118-01-8]